Boston Scientific Obtains CE Mark for Image Guided Programming Software for Deep Brain Stimulation
Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions

HEMEL HEMPSTEAD, United Kingdom – 20 June 2024 – Boston Scientific Corporation (NYSE: BSX) has obtained CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide clinicians with simple and actionable data for efficient programming in the treatment of people living with Parkinson’s disease, essential tremor and dystonia.

“We are now using image guided programming tools to optimally define the site of stimulation while we clinically assess the patient,” said Francesca Morgante, professor of Neurology and Eleonor Peel Chair for the study of Ageing at St. George’s University of London. ”This advancement in the technology has substantially cut down our programming time and allowed to improve the symptoms of our patients in a significant shorter time.”

The Vercise Neural Navigator 5 Software, with STIMVIEW XT technology, is the latest addition to the fully integrated portfolio of image guided programming solutions for Boston Scientific DBS Systems. Developed in collaboration with Brainlab, a leading software-driven medical technology company, these tools have demonstrated a reduction in programming time by 56%1 and provide real-time visualization and stimulation of each person’s unique brain anatomy.

The software includes an enhanced user interface that displays patient data in a simplified format and gives clinicians access to advanced settings for increased therapy delivery. The software is designed to enable more flexibility to better manage the evolving needs of individual patients at any stage of their condition.

"Our aim is to develop tools that make a meaningful difference to physicians and to people living with neurological conditions alike,” said Vincent Sourdaine, vice president, Neuromodulation in Europe, Middle East and Africa (EMEA), Boston Scientific. “This software enables more efficiency with DBS therapy to simplify what can otherwise be a time-consuming procedure, freeing up capacity for hospitals and clinicians for more value-added tasks and to provide optimal care for patients.”

For more information about the Vercise Genus DBS Systems and image guided programming please visit the dedicated VN5 website.



About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit and connect on LinkedIn and X, formerly Twitter.


Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.




Uchenna Izundu

Media Relations, UK and Ireland



1Lange, F et al. Reduced Programming Time and Strong Symptom Control Even in Chronic Course Through Imaging-Based DBS Programming, Front Neurol 2021 Nov 8;12:785529